Challenges encountered in the enantioselective analysis of new psychoactive substances exemplified by clephedrone (4-CMC)
Jorbenadze, Saba (Tbilisi State University (Geòrgia))
Khatiashvili, Tamar (Università Politecnica delle Marche (Ancona, Itàlia))
Giunashvili, Lasha (Tbilisi State University (Geòrgia))
Tchelidze, Aluda (Tbilisi State University (Geòrgia))
Lo Faro, Alfredo Fabrizio (Università Politecnica delle Marche (Ancora, Itàlia))
Pichini, Simona (Istituto Superiore di Sanità)
Farré Albaladejo, Magí (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Papaseit, Ester (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Nuñez-Montero, Melani (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Carlier, Jeremy (Department of Excellence-Biomedical Sciences and Public Health. Università Politecnica delle Marche)
Farkas, Tivadar (Tbilisi State University (Geòrgia))
Busardo, Francesco Paolo (Università Politecnica delle Marche (Ancora, Itàlia))
Chankvetadze, Bezhan (Tbilisi State University (Geòrgia))
Universitat Autònoma de Barcelona

Data:	2024
Resum:	In this study we report on efforts to develop an enantioselective method for the detection of the drug of abuse clephedrone (1-(4-chlorophenyl)-2-(methylamino)-1-propanone (4-chloromethcathinone, also known as 4-CMC or para-chloro-methcathinone)) and its phase-1 metabolites in human biological fluids. The major goal is not to only report results, but primarily to emphasize the various challenges encountered when developing a reliable analytical method for the detection and quantification of novel psychoactive substances (NPS) and their metabolites in the matrix of interest. Such challenges start with the lack of chemical stability of some NPS in biological matrices. Additionally, most often metabolites are unavailable in pure form to serve as analytical standards, just as deuterated standards for native drugs and metabolites are frequently not commercially available. Furthermore, if the NPS is chiral, enantiomerically pure standards with known absolute stereochemistry are required, as well as a stereochemical stability of a drug and its metabolites becomes an issue. In addition, the chirality of a NPS significantly increases the number of species to be detected in the sample and thus challenges the development of an adequate separation method. These issues are shortly addressed, and some solutions offered in this manuscript.
Ajuts:	Instituto de Salud Carlos III PI17/01962 Instituto de Salud Carlos III PI20/00879 European Commission RD21/0009/0004
Drets:	Aquest material està protegit per drets d'autor i/o drets afins. Podeu utilitzar aquest material en funció del que permet la legislació de drets d'autor i drets afins d'aplicació al vostre cas. Per a d'altres usos heu d'obtenir permís del(s) titular(s) de drets.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Publicat a:	Journal of Pharmaceutical and Biomedical Analysis, Vol. 248 (15 2024) , p. 116275, ISSN 1873-264X

DOI: 10.1016/j.jpba.2024.116275

10 p, 3.1 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Articles de recerca
Articles > Articles publicats